PMID- 12807853
OWN - NLM
STAT- MEDLINE
DCOM- 20030714
LR  - 20220409
IS  - 1468-201X (Electronic)
IS  - 1355-6037 (Print)
IS  - 1355-6037 (Linking)
VI  - 89
IP  - 7
DP  - 2003 Jul
TI  - Adverse events in coronary artery bypass graft (CABG) trials: a systematic review 
      and analysis.
PG  - 767-72
AB  - OBJECTIVES: To quantify the incidence of major adverse events (AEs) occurring in 
      hospital or within 30 days after surgery in patients undergoing coronary artery 
      bypass graft (CABG) surgery and to identify risk factors for these AEs. METHODS: 
      Systematic review and analysis of studies published in English since 1990. 
      Studies of isolated standard CABG reporting postoperative incidence of myocardial 
      infarction (MI), stroke, gastrointestinal bleeding, renal failure, or death in 
      hospital or within 30 days were eligible for inclusion. Incidence of these events 
      was calculated overall and for selected patient groups defined by all elective 
      CABG versus mixed (some non-elective); mean ejection fraction < or = 50% versus > 
      50%; mean age < or= 60 versus > 60 years; primary CABG versus some reoperations; 
      randomised controlled trials versus cohort studies; and single centre versus 
      multicentre studies. Odds ratios of selected AEs were computed according to group 
      risk factors. RESULTS: 176 studies (205 717 patients) met all inclusion criteria. 
      The average incidence of major AEs occurring in-hospital was death (1.7%); 
      non-fatal MI (2.4%); non-fatal stroke (1.3%); gastrointestinal bleeding (1.5%); 
      and renal failure (0.8%). Thirty day mortality was 2.1%. Meta-analyses show that 
      age > 70, female sex, low ejection fraction, history of stroke, MI, or heart 
      surgery, and presence of diabetes or hypertension are all associated with 
      increased 30 day mortality after CABG. CONCLUSION: The incidence of major AEs in 
      patients after CABG varies widely across studies and patient populations, and 
      this heterogeneity must be controlled when using the literature to benchmark 
      safety.
FAU - Nalysnyk, L
AU  - Nalysnyk L
AD  - MetaWorks CABG Review Group, MetaWorks Inc, Medford, Massachusetts 02155, USA. 
      LNalysnyk@metawork.com
FAU - Fahrbach, K
AU  - Fahrbach K
FAU - Reynolds, M W
AU  - Reynolds MW
FAU - Zhao, S Z
AU  - Zhao SZ
FAU - Ross, S
AU  - Ross S
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
PL  - England
TA  - Heart
JT  - Heart (British Cardiac Society)
JID - 9602087
SB  - IM
MH  - Aged
MH  - Coronary Artery Bypass/*adverse effects/mortality
MH  - Death, Sudden
MH  - Female
MH  - Gastrointestinal Hemorrhage/etiology/mortality
MH  - Hospitalization
MH  - Humans
MH  - Male
MH  - Myocardial Infarction/etiology/mortality
MH  - Renal Insufficiency/etiology/mortality
MH  - Risk Assessment
MH  - Risk Factors
MH  - Sensitivity and Specificity
MH  - Stroke/etiology
PMC - PMC1767742
EDAT- 2003/06/17 05:00
MHDA- 2003/07/15 05:00
PMCR- 2006/07/01
CRDT- 2003/06/17 05:00
PHST- 2003/06/17 05:00 [pubmed]
PHST- 2003/07/15 05:00 [medline]
PHST- 2003/06/17 05:00 [entrez]
PHST- 2006/07/01 00:00 [pmc-release]
AID - 0890767 [pii]
AID - 10.1136/heart.89.7.767 [doi]
PST - ppublish
SO  - Heart. 2003 Jul;89(7):767-72. doi: 10.1136/heart.89.7.767.